189 related articles for article (PubMed ID: 19593173)
1. Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response.
Salomoni G; Grassi M; Mosini P; Riva P; Cavedini P; Bellodi L
J Clin Psychopharmacol; 2009 Aug; 29(4):343-9. PubMed ID: 19593173
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
3. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
4. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
5. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
6. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J
J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364
[TBL] [Abstract][Full Text] [Related]
8. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Wheaton MG; Rosenfield D; Foa EB; Simpson HB
J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
[TBL] [Abstract][Full Text] [Related]
9. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
10. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
[TBL] [Abstract][Full Text] [Related]
11. Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
McLean CP; Zandberg LJ; Van Meter PE; Carpenter JK; Simpson HB; Foa EB
J Clin Psychiatry; 2015 Dec; 76(12):1653-7. PubMed ID: 26613263
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
13. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Saxena S; Wang D; Bystritsky A; Baxter LR
J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
[TBL] [Abstract][Full Text] [Related]
14. How resistant is 'treatment-resistant' obsessive-compulsive disorder in youth?
Krebs G; Isomura K; Lang K; Jassi A; Heyman I; Diamond H; Advani J; Turner C; Mataix-Cols D
Br J Clin Psychol; 2015 Mar; 54(1):63-75. PubMed ID: 25130442
[TBL] [Abstract][Full Text] [Related]
15. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Stein DJ; Bouwer C; Hawkridge S; Emsley RA
J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
[TBL] [Abstract][Full Text] [Related]
16. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
[TBL] [Abstract][Full Text] [Related]
17. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Pfanner C; Marazziti D; Dell'Osso L; Presta S; Gemignani A; Milanfranchi A; Cassano GB
Int Clin Psychopharmacol; 2000 Sep; 15(5):297-301. PubMed ID: 10993132
[TBL] [Abstract][Full Text] [Related]
18. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
Ramasubbu R
Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
[No Abstract] [Full Text] [Related]
19. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
20. Treatment of compulsive hoarding.
Saxena S; Maidment KM
J Clin Psychol; 2004 Nov; 60(11):1143-54. PubMed ID: 15389621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
